Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2021-02-04 Director's Dealing
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
110年01月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and stock ownership information of company insiders, including directors, managers, and their related parties. It includes data on shares held, increases, decreases, and trust shares. The content is focused on insider shareholdings and changes thereof. There is no indication of financial statements, earnings data, meeting materials, or legal proceedings. The document is a notification of insider shareholdings and transactions by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is substantial and contains actual data, not just an announcement or certification.
2021-02-04 Chinese
110年01月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司. It lists positions such as Chairman, Vice Chairman, Directors, Independent Directors, General Manager, Deputy General Managers, Managers, and major shareholders, along with their shareholdings and pledged shares. The document includes notes about the company's organizational structure and clarifications on shareholding calculations. There is no indication of financial statements, earnings data, management discussion, or regulatory certifications. The content focuses on insider shareholdings and related disclosures, which aligns with reporting on insider transactions or holdings. Given the nature of the data—reporting personal share transactions or holdings by company directors and executives—this fits the definition of Director's Dealing (DIRS). The document length is 3148 characters, which is relatively short but contains detailed insider shareholding data rather than a mere announcement or certification. Therefore, the best classification is DIRS with high confidence.
2021-02-04 Chinese
公告本公司單一事件罰鍰金額累計達新台幣壹佰萬元以上。
Legal Proceedings Report Classification · 95% confidence The document is a regulatory announcement from a listed company (4119 旭富) reporting on the accumulation of fines exceeding one million New Taiwan Dollars due to various violations including fire incident consequences and labor law breaches. It details the nature of the fines, legal references, and corrective actions. The document is short (1017 characters) and serves as a factual disclosure of a regulatory/legal matter rather than a financial report or management discussion. It does not contain financial statements, earnings data, or detailed report content. Therefore, it fits best under Legal Proceedings Report (LTR) as it updates on significant regulatory/legal actions involving the company.
2021-02-03 Chinese
依據臺證上一字第1091806531號函辦理及補充說明。
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (旭富製藥科技股份有限公司) providing supplementary information and clarifications related to a regulatory inquiry (臺證上一字第1091806531號函). It includes financial figures as of December 31, 2020, such as cash, financial assets, short-term borrowings, and details about asset losses due to fire damage. The document is only 1728 characters long, which is quite brief and does not contain comprehensive financial statements or detailed analysis. It appears to be a regulatory disclosure or compliance update rather than a full financial report or earnings release. There is no indication that this is a full annual or interim report, audit report, or earnings release. It also does not fit into categories like management changes, capital updates, or legal proceedings. Given the nature and length, this fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-01-13 Chinese
109年12月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and stock pledges by company insiders, including directors, supervisors, and senior management. It lists current holdings, pledged shares, and related percentages. The content focuses on insider shareholdings and their status, which aligns with disclosures about personal share transactions or holdings by company directors and executives. There is no indication of financial results, meeting materials, voting results, or other report types. The document length is 3148 characters, which is relatively short but contains detailed insider shareholding data rather than a mere announcement. Therefore, the document fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2021-01-12 Chinese
109年12月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, managers, and their related parties. It includes data on shares held at appointment, changes during the month, and current holdings. The content is focused on insider share transactions and holdings, not on financial results, management changes, or meeting materials. There is no indication of a report or announcement of a report, nor is there any narrative or financial data. This type of document corresponds to a Director's Dealing report, which discloses personal share transactions by company directors and executives.
2021-01-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.